Efficacy and safety of once-weekly semaglutide vs sitagliptin as add-on to metformin and/or thiazolidinediones after 56 weeks in subjects with type 2 diabetes (SUSTAIN 2)

被引：0
|
作者：
Ahren, B. [1 ]
Comas, L. Masmiquel [2 ]
Kumar, H. [3 ]
Sargin, M. [4 ]
Karsbol, J. Derving [5 ]
Jacobsen, S. Hald [5 ]
Chow, F. [6 ]
机构：
[1] Lund Univ, Lund, Sweden
[2] Hosp Quiron Palmaplanas, Palma De Mallorca, Spain
[3] Amrita Inst Med Sci & Res Ctr, Kochi, India
[4] Kartal Lufti Kirdar Training & Res Hosp, Istanbul, Turkey
[5] Novo Nordisk AS, Soborg, Denmark
[6] Chinese Univ Hong Kong, Shatin, Hong Kong, Peoples R China
来源：
DIABETOLOGIA | 2016年 / 59卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
767
引用
收藏
页码：S365 / S365
页数：1
相关论文
共 50 条
  • [31] Efficacy and safety of once-weekly semaglutide low dose 0.5 mg vs once-weekly dulaglutide high dose 1.5 mg in type 2 diabetes: a post hoc analysis of SUSTAIN 7
    Pratley, R. E.
    Aroda, V. R.
    Gondolf, T.
    Hansen, T.
    Lingvay, I.
    Ludemann, J.
    Skjoth, T. V.
    Viljoen, A.
    DIABETOLOGIA, 2019, 62 : S374 - S374
  • [32] Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial
    Ahmann, Andrew J.
    Capehorn, Matthew
    Charpentier, Guillaume
    Dotta, Francesco
    Henkel, Elena
    Lingvay, Ildiko
    Holst, Anders G.
    Annett, Miriam P.
    Aroda, Vanita R.
    DIABETES CARE, 2018, 41 (02) : 258 - 266
  • [33] Efficacy and safety of semaglutide 1.0 mg once weekly vs liraglutide 1.2 mg once daily as add-on to 1-3 oral glucose-lowering drugs in subjects with type 2 diabetes (SUSTAIN 10)
    Capehorn, M. S.
    Catarig, A. -M.
    Furberg, J. K.
    Janez, A.
    Price, H. C.
    Tadayon, S.
    Verges, B.
    Marre, M.
    DIABETOLOGIA, 2019, 62 : S28 - S29
  • [34] Efficacy and safety of semaglutide 1.0mg once weekly vs liraglutide 1.2mg once daily as add-on to 1-3 oral antidiabetic drugs in subjects with Type 2 diabetes (SUSTAIN 10)
    Capehorn, M.
    Janez, A.
    Price, H.
    Verges, B.
    Catarig, A. M.
    Furberg, J. Kjaerulff
    Tadayon, S.
    Marre, M.
    DIABETIC MEDICINE, 2019, 36 : 172 - 172
  • [35] Effect of once-weekly semaglutide on insulin use in subjects with type 2 diabetes: a post hoc analysis of SUSTAIN 6
    Seufert, J.
    Desouza, C.
    Kirk, A. R.
    Lawson, J.
    Lingvay, I.
    Sondergaard, A. L.
    Bain, S. C.
    DIABETOLOGIA, 2021, 64 (SUPPL 1) : 251 - 252
  • [36] Effects of once-weekly semaglutide vs canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 trial
    McCrimmon, R. J.
    Catarig, A.
    Frias, J. P.
    Lausvig, N. L.
    le Roux, C. W.
    Thielke, D.
    Lingvay, I.
    DIABETOLOGIA, 2019, 62 : S29 - S29
  • [37] The Efficacy and Safety of Once-Weekly Dosing of Polyethylene Glycol Loxenatide (PEX168) as an Add-on Therapy to Metformin in Chinese Patients with Type 2 Diabetes
    Chen, Xiao-Ping
    Yang, Wen-Ying
    Lv, Xiao-Feng
    Yang, Gang-Yi
    Li, Ya-Lin
    Wang, Qiang
    Shen, Joan Huaqiong
    DIABETES, 2014, 63 : A605 - A605
  • [38] The effects of once-weekly semaglutide on beta cell function in subjects with type 2 diabetes
    Kapitza, C.
    Dahl, K.
    Jacobsen, J. Bonde
    Axelsen, M. Buhl
    Flint, A.
    DIABETOLOGIA, 2016, 59 : S358 - S359
  • [39] Efficacy of Once-Weekly Semaglutide vs Empagliflozin Added to Metformin in Type 2 Diabetes: Patient-Level Meta-analysis
    Lingvay, Ildiko
    Capehorn, Matthew S.
    Catarig, Andrei-Mircea
    Johansen, Pierre
    Lawson, Jack
    Sandberg, Anna
    Shaw, Robert
    Paine, Abby
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2020, 105 (12):
  • [40] Efficacy and safety of lobeglitazone versus sitagliptin as an add-on to metformin in patients with type 2 diabetes and metabolic syndrome over 24-weeks
    Kim, D.
    Kim, S.
    Yoon, K.
    Chun, S.
    Park, K.
    Choi, K.
    Lim, S.
    Mok, J.
    Lee, H.
    Seo, J.
    Cha, B.
    Kim, M. -K.
    Shon, H.
    Choi, D.
    DIABETOLOGIA, 2019, 62 : S428 - S428
12345